



A Letter from the Founder

Hello Members,

Thank you for your continued support. We strive for the CCTC to continually provide you with consolidated and up-to-date information about open clinical trials for your patients.

Please let us know if you have any suggestions to improve the user experience of the website.

Sincerely,

Dr. Christine Brezden-Masley

A Letter from the Project Manager

Hi everyone,

A friendly reminder to consider posting your trials on the COMET website as they open to recruitment at your center! I am also happy to post on your behalf. Simply send me an email with the names of the trial, principal investigator and research coordinator.

As always, please share this newsletter with any colleagues who may be interested in joining the network.

Kind Regards,

Alexandra Moskalewicz

ARTICLE RECOMMENDATION

Financial Toxicity and Equitable Access to Clinical Trials.

Chino F, Zafar SY. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:11-18. doi: 10.1200/EDBK_100019

ABSTRACT:

Financial barriers to clinical trial enrollment are an area of active investigation. Financial toxicity as a concept describes how high costs and financial burden can lead to compromised care and outcomes. Despite the potential to yield large survival benefits and improved access to cutting-edge therapies, less than 5% of adult patients with cancer are enrolled in a clinical trial. Disparities in trial enrollment exist along age, ethnic, and sociodemographic lines, with younger, poorer, nonwhite patients with private insurance-the exact population who may be at highest risk for financial toxicity-less likely to participate. Cost and insurance concerns remain an obstacle for clinical trial enrollment for certain patient populations. Changing the clinical trial paradigm with a focus on addressing structural and clinical barriers to clinical trial enrollment is paramount. This includes expanding access to clinical trials within community populations, advocating for health policy changes to guarantee insurance coverage of clinical trial standard-of-care health care, and considering non-coercive financial assistance (particularly for indirect costs like travel and lodging) for participants to defray their additional costs of participation. Additional steps toward education, cost transparency, and expansion of foundation assistance may also improve equitable access to clinical trials for all.

TRIALS SNAPSHOT

Trial Type	Imaging	Observational	Prevention	Radiation Therapy	Supportive Care	Surgical Therapy	Systemic Therapy	Therapeutic	Total
Any Malignancy		1	2	2			5		10
Breast	2	3		4	2	2	11		24
CNS				1				1	2
GI		1	1	3			11	1	17
GU	1			3		1	17	1	23
Gyne		1				1	9		11
Head&Neck				2	1	1	3	2	9
Heme		2	1				11	1	15
Lung				10			8	1	19
Melanoma							5		5
Skin							2		2
Sarcoma		1							1
NET							1		1
Total	3	9	4	25	3	5	83	7	139



TRIALS OF THE MONTH

Type	Acronym	Study Title	Description	Participating Site(s) on COMET
Breast	CAPITELLO-290	A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC)	<ul style="list-style-type: none"> • Triple-Negative Breast Cancer • Systemic Therapy 	North York General Hospital
GU	GALAHAD	A Phase II Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies	<ul style="list-style-type: none"> • Metastatic Castration-Resistant Prostate Cancer • Systemic Therapy 	Sunnybrook Health Sciences Centre
GI	EMERALD-1	A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination With Either Durvalumab Monotherapy or Durvalumab Plus Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma	<ul style="list-style-type: none"> • Hepatocellular Carcinoma • Systemic Therapy 	Sunnybrook Health Sciences Centre
Heme	MCRN-009	A Phase II Open Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma	<ul style="list-style-type: none"> • Relapsed and Refractory Multiple Myeloma • Systemic Therapy 	Kingston General Hospital
Lung	KEYNOTE-495	A Phase II Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer	<ul style="list-style-type: none"> • Non-Small Cell Lung Cancer • Systemic Therapy 	Sunnybrook Health Sciences Centre
Gyne	OVC.2	A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)	<ul style="list-style-type: none"> • Ovarian, Fallopian Tube, or Peritoneal Cancer • Systemic Therapy 	Royal Victoria Regional Health Centre
Any	SPARE-HF	Randomized Double Blind Placebo Controlled Trial of Statins for the Primary pREvention of Heart Failure in Patients With Cancer Receiving Anthracycline Based Chemotherapy	<ul style="list-style-type: none"> • Patients receiving anthracycline based chemotherapy 	Toronto General Hospital, St. Michael's Hospital, Sunnybrook Health Sciences Centre



Click here to NOMINATE your trial for Trials of the Month!




MEMBERSHIP UPDATES

139 accruing trials

300 members

30 institutions



ACKNOWLEDGEMENTS

The CCTC has been funded by unrestricted educational grants from the following supporters in 2018/2019:



CONTACT US

Do you have any questions, feedback, suggestions? Please do not hesitate to contact us.

cometrials@smh.ca

30 Bond Street
Toronto, ON Canada
M5B 1W8

www.cometrials.com

INSTITUTIONS

	Location	Trials	Members
Cambridge Memorial Hospital	Cambridge	3	3
Grand River Hospital	Kitchener	-	7
Humber River Regional Hospital	Toronto	1	5
Kingston General Hospital	Kingston	32	3
Juravinski Cancer Centre	Hamilton	1	7
Lakeridge Health Corporation	Oshawa	-	20
London Health Sciences Centre	London	75	12
Mackenzie Health Hospital	Richmond Hill	-	6
Markham Stouffville Hospital	Markham	-	5
Mount Sinai Hospital	Toronto	1	4
North York General Hospital	Toronto	4	13
Sunnybrook Health Sciences Centre	Toronto	52	68
Ontario Institute for Cancer Research	Toronto	-	4
Ontario Hospital	Toronto	-	1
Ottawa Hospital	Ottawa	1	3
Princess Margaret Cancer Centre	Toronto	-	28
Quinte Health Care	Belleville	-	1
Rouge Valley Health System	Ajax	-	3
Royal Victoria Regional Health Centre	Barrie	13	23
Scarborough General Hospital	Toronto	-	3
Southlake Regional Health Centre	Newmarket	5	20
St. Joseph's Healthcare	Hamilton	-	4
St. Joseph's Health Centre	Toronto	-	3
St. Michael's Hospital	Toronto	7	13
Sudbury Regional Hospital	Sudbury	-	1
Thunder Bay Regional	Thunder Bay	-	2
Toronto General Hospital	Toronto	2	4
Trillium Health Partners	Mississauga	3	18
William Osler Health Systems	Brampton	-	3
Windsor Regional Hospital	Windsor	-	2